TG Therapeutics, Inc. (NASDAQ:TGTX) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 17,557,367 shares, an increase of 16.3% from the October 13th total of 15,097,551 shares. Approximately 32.2% of the company’s shares are sold short. Based on an average daily trading volume, of 2,154,519 shares, the short-interest ratio is currently 8.1 days.

Shares of TG Therapeutics (NASDAQ TGTX) opened at $8.25 on Tuesday. TG Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. equities research analysts anticipate that TG Therapeutics will post -1.79 earnings per share for the current year.

A number of analysts have recently commented on TGTX shares. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a report on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $25.11.

A number of institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its position in TG Therapeutics by 4.1% during the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 384 shares during the period. Bank of America Corp DE boosted its position in TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,395 shares during the period. American International Group Inc. boosted its position in TG Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 1,500 shares during the period. California State Teachers Retirement System boosted its position in TG Therapeutics by 1.9% during the 2nd quarter. California State Teachers Retirement System now owns 85,935 shares of the biopharmaceutical company’s stock worth $864,000 after purchasing an additional 1,600 shares during the period. Finally, UBS Group AG boosted its position in TG Therapeutics by 34.4% during the 1st quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 3,736 shares during the period. 49.58% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/tg-therapeutics-inc-tgtx-short-interest-update/1701374.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.